اعتیاد به مواد مخدر و الکل
ترجمه نشده

اعتیاد به مواد مخدر و الکل

عنوان فارسی مقاله: گیرنده های نوروکینین در اعتیاد به مواد مخدر و الکل
عنوان انگلیسی مقاله: Neurokinin Receptors in Drug and Alcohol Addiction
مجله/کنفرانس: تحقیقات مغز – Brain Research
رشته های تحصیلی مرتبط: پزشکی
گرایش های تحصیلی مرتبط: مغز و اعصاب، روانپزشکی
کلمات کلیدی فارسی: نوروکینین، ماده P، استقرار مجدد، استرس، اعتیاد، الکل
کلمات کلیدی انگلیسی: Neurokinin، Substance P، Reinstatement، Stress، Addiction، Alcohol
نوع نگارش مقاله: مقاله مروری (Review Article)
شناسه دیجیتال (DOI): https://doi.org/10.1016/j.brainres.2020.146729
دانشگاه: University of Georgia, Department of Physiology and Pharmacology, Athens, GA 30602, USA
صفحات مقاله انگلیسی: 35
ناشر: الزویر - Elsevier
نوع ارائه مقاله: ژورنال
نوع مقاله: ISI
سال انتشار مقاله: 2020
ایمپکت فاکتور: 3.002 در سال 2019
شاخص H_index: 188 در سال 2020
شاخص SJR: 1.364 در سال 2019
شناسه ISSN: 0006-8993
شاخص Quartile (چارک): Q2 در سال 2019
فرمت مقاله انگلیسی: PDF
وضعیت ترجمه: ترجمه نشده است
قیمت مقاله انگلیسی: رایگان
آیا این مقاله بیس است: خیر
آیا این مقاله مدل مفهومی دارد: ندارد
آیا این مقاله پرسشنامه دارد: ندارد
آیا این مقاله متغیر دارد: ندارد
کد محصول: E14880
رفرنس: دارای رفرنس در داخل متن و انتهای مقاله
فهرست مطالب (انگلیسی)

Abstract

Abbreviations

۱٫ Introduction

۲٫ Monoamine signaling

۳٫ Reward behavior

۴٫ Opiate reward and reinforcement

۵٫ Cocaine-Induced behaviors

۶٫ Alcohol reward and reinforcement

۷٫ Nicotine-Related behaviors

۸٫ Reinstatement of drug seeking

۹٫ Summary of preclinical findings

۱۰٫ Therapeutics & clinical research

۱۱٫ Conclusions

Acknowledgement

References

بخشی از مقاله (انگلیسی)

Abstract

The neurokinins are a class of peptide signaling molecules that mediate a range of central and peripheral functions including pain processing, gastrointestinal function, stress responses, and anxiety. Recent data have linked these neuropeptides with drug-related behaviors. Specifically, substance P (SP) and neurokinin B (NKB), have been shown to influence responses to alcohol, cocaine, and/or opiate drugs. SP and NKB preferentially bind to the neurokinin-1 receptor (NK1R) and neurokinin-3 receptor (NK3R), respectively, but do have some affinity for all classes of neurokinin receptor at high concentrations. NK1R activity has been shown to influence reward and reinforcement for opiate drugs, stimulatory and neurochemical responses to cocaine, and escalated and stress-induced alcohol seeking. In reinstatement models of relapselike behavior, NK1R antagonism attenuates stress-induced reinstatement for all classes of drugs tested to date. The NK3R also influences alcohol intake and behavioral/neurochemical responses to cocaine, but less research has been performed in regard to this particular receptor in preclinical models of addiction. Clinically, agents targeting these receptors have shown some promise, but have produced mixed results. Here, the preclinical findings for the NK1R and NK3R are reviewed, and discussion is provided to interpret clinical findings. Additionally, important factors to consider in regards to future clinical work are suggested.

Introduction

There are three primary neurokinin peptides, Substance P (SP), Neurokinin A (NKA) and Neurokinin B (NKB). The neurokinin class of peptides is part of the tachykinin family and the associated nomenclature is influenced by this classification (see below). SP and NKA are produced by the preprotachykinin-a (PPTA) propeptide and NKB is produced by preprotachykinin-b (PPTB) propeptide. Other tachykinin peptides including Neuropeptide K and Neuropeptide γ are formed by alternative splicing of the PPTA mRNA, but will not be discussed in this review[1]. Neurokinin systems play a diverse role in physiological processes including regulation of pain processing, cardiovascular function, intestinal motility, and complex behaviors such as stress responses and drug seeking. Genetic association studies have implicated a role of neurokinin receptors in alcohol abuse, attention deficit hyperactivity disorder, and bipolar disorder[2-4]. Also, medications targeting these receptors have been tested for the treatment of depression, substance abuse, and menopausal hot flashes[5-11]. One FDA-approved medication, the neurokinin-1 receptor antagonist aprepitant, is currently in use to treat chemotherapy-induced nausea.